Reimbursement for Corneal Collagen Cross-Linking
Corneal collagen cross-linking (CXL) uses a combination of riboflavin (vitamin B2) and ultraviolet (UVA) light to make collagen in the corneal stroma stronger and more flexible. In keratoconus and corneal ectasia, the corneal stroma has weakened, the cornea thins and bulges out, distorting vision. In most cases, CXL is ideally performed early in the disease process before vision deteriorates to the point where glasses or contact lenses no longer correct vision.
This FAQ addresses the following:
- What is corneal collagen cross-linking?
- What is involved in the CXL procedure?
- What conditions are treated with CXL?
- Has CXL been approved by the FDA?
- What CPT code should be used to report CXL?
- Is riboflavin (B2) separately reported on a claim for reimbursement?
- Is CXL covered by health insurance?
- What is the global period for 0402T?
- If coverage of CXL is unlikely or uncertain, how should we proceed?
Purchase This Resource:
Purchase the FAQ Library:
For best results, please view in Mozilla Firefox.